Bladder cancer is relatively common in the EU. Most cases are non-muscle-invasive bladder cancer (NMIBC), classified into risk groups based on their chance of progression, which determines the frequency and duration of monitoring after treatment. We created a flexible tool to estimate the burden of NMIBC cases in eleven European countries and estimated the number of monitoring cystoscopies by risk group based on national and regional guidelines.
Vecino-Ortiz AI, Glover RE, Adams EJ. Modelling the burden of non-muscle-invasive bladder cancer in Europe. European Association of Urology. 11-15 March 2016. Munich, Germany.